P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12

被引:40
作者
Zhang, LY
Ibbotson, RE
Orchard, JA
Gardiner, AC
Seear, RV
Chase, AJ
Oscier, DG
Cross, NCP
机构
[1] Wessex Reg Genet Lab, Salisbury, Wilts, England
[2] Shandong Univ, Shandong Prov Hosp, Jinan 250100, Peoples R China
[3] Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England
关键词
P2X7; CLL; trisomy; 12;
D O I
10.1038/sj.leu.2403125
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The P2X7 receptor, a plasma membrane ATP-gated ion channel that plays a role in lymphocyte apoptosis, has been suggested as an important contributory factor to the pathogenesis of chronic lymphocytic leukaemia (CLL). The P2X7 gene resides on chromosome 12 and is polymorphic in the population at large (1513A/C) with the A and C alleles encoding fully active and nonfunctional proteins, respectively. We have evaluated the significance of this polymorphism by genotyping 144 patients with CLL and 348 healthy controls using a tetraprimer ARMS assay. We found no significant difference in allele frequency between patients and controls. Although patients with the C allele (A/C heterozygotes or C/C homozygotes) had a marginally shorter survival than those who were homozygous for the A allele, this difference was not significant for either the patient group considered as a whole or for IgVH-mutated/unmutated subsets. Finally, no association was found between trisomy 12 and P2X7 genotype. We conclude that the influence, if any, of P2X7 genotype on susceptibility to CLL or clinical outcome is small.
引用
收藏
页码:2097 / 2100
页数:4
相关论文
共 17 条
[1]   P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia [J].
Adinolfi, E ;
Melchiorni, L ;
Falzoni, S ;
Chiozzi, P ;
Morelli, A ;
Tieghi, A ;
Cuneo, A ;
Castoldi, G ;
Di Virgilio, F ;
Baricordi, OR .
BLOOD, 2002, 99 (02) :706-708
[2]  
BritoBabapulle V, 1997, ACTA HAEMATOL-BASEL, V98, P175
[3]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[4]   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847
[5]   A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor [J].
Gu, BJ ;
Zhang, WY ;
Worthington, RA ;
Sluyter, R ;
Dao-Ung, P ;
Petrou, S ;
Barden, JA ;
Wiley, JS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) :11135-11142
[6]   Chronic lymphocytic leukaemia: one disease or two? [J].
Hamblin, T .
ANNALS OF HEMATOLOGY, 2002, 81 (06) :299-303
[7]   Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia [J].
Hamblin, TJ ;
Davis, Z ;
Gardiner, A ;
Oscier, DG ;
Stevenson, FK .
BLOOD, 1999, 94 (06) :1848-1854
[8]  
Mattocks C, 2000, HUM MUTAT, V16, P437, DOI 10.1002/1098-1004(200011)16:5<437::AID-HUMU9>3.3.CO
[9]  
2-H
[10]   Multivariate analysis of prognostic factors in CLL:: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors [J].
Oscier, DG ;
Gardiner, AC ;
Mould, SJ ;
Glide, S ;
Davis, ZA ;
Ibbotson, RE ;
Corcoran, MM ;
Chapman, RM ;
Thomas, PW ;
Copplestone, JA ;
Orchard, JA ;
Hamblin, TJ .
BLOOD, 2002, 100 (04) :1177-1184